Metformin and cancer mortality
The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/5491 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327292263694336 |
|---|---|
| author | Lev Mikhaylovich Bershteyn |
| author_facet | Lev Mikhaylovich Bershteyn |
| author_sort | Lev Mikhaylovich Bershteyn |
| collection | DOAJ |
| description | The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized. |
| format | Article |
| id | doaj-art-05da729af1a04fbb8decb7c01a66bd6a |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2010-09-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-05da729af1a04fbb8decb7c01a66bd6a2025-08-20T03:47:54ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-09-01133667010.14341/2072-0351-54915449Metformin and cancer mortalityLev Mikhaylovich Bershteyn0ФГУ НИИ онкологии им. Н.Н. Петрова, Санкт-ПетербургThe author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized.https://www.dia-endojournals.ru/jour/article/view/5491metformindiabetes mellitusoncological diseases |
| spellingShingle | Lev Mikhaylovich Bershteyn Metformin and cancer mortality Сахарный диабет metformin diabetes mellitus oncological diseases |
| title | Metformin and cancer mortality |
| title_full | Metformin and cancer mortality |
| title_fullStr | Metformin and cancer mortality |
| title_full_unstemmed | Metformin and cancer mortality |
| title_short | Metformin and cancer mortality |
| title_sort | metformin and cancer mortality |
| topic | metformin diabetes mellitus oncological diseases |
| url | https://www.dia-endojournals.ru/jour/article/view/5491 |
| work_keys_str_mv | AT levmikhaylovichbershteyn metforminandcancermortality |